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Preventing hemorrhage in high-risk hemodialysis: Regional
versus low-dose heparin
RICHARD D. SWARTZ and FRIEDRICH K. PORT
Division of Nephro/ogy, Department of Internal Medicine, University of Michigan Medical School and Veterans
Administration Hospital, Ann Arbor, Michigan
Preventing hemorrhage in high-risk hemodialysis: Regional ver-
sus low-dose heparin. Hemodialysis in patients with increased
risk for hemorrhage can be accomplished with either a regional
or a low, total dose of heparin. In a prospective study of 69 series
of dialyses performed on an alternating schedule of hepariniza-
tion for each patient, bleeding complications during and immedi-
ately following dialysis occurred in 23 of 122 dialyses (19%) with
regional heparin compared to 13 of 133 dialyses (10%) with low-
dose heparin (P <0.05). The incidence of hemorrhage correlated
with the estimated degree of bleeding risk both at expected and
at occult bleeding sites, and was the same or higher with regional
heparin in all categories. Hemorrhage was not correlated with
preexisting coagulation abnormalities, concurrent anticoagulant
drugs, level of azotemia, or ability to successfully limit systemic
heparinization during dialysis. The incidence of partial clotting of
the dialyzer was 3 to 5% with both hepann protocols. We con-
clude that regional heparinization has no clinical or practical ad-
vantage dyer low-total-dose heparin in preventing bleeding asso-
ciated with hemodialysis.
Prevention de l'hemorragie au cours de t'hémodialyse a haut
risque: Héparinisation régionale ou héparinisation a faibles doses.
L'hémodialyse des malades dont le risque hémorragique est
élevé peut être réalisée soit avec une héparinisation régionale
soit avec une dose totale faible d'héparine. Au cours d'une étude
prospective portant sur 69 series de dialyses réalisées selon un
protocole oO les modes d'heparinisation étaient alternés chez
chaque malade, les complications hemorragiques au cours et au
décours immédiat de Ia dialyse ont été observées dans 23 dial-
yses sur 122 (19%) conduites avec une héparinisation régionale
et 13 dialyses sur 133 (10%) réalisées avec une faible dose
d'héparine (P < 0,05). La fréquence des hémorragies était cor-
rélée avec l'évaluation du risque de saignement et elle a été Ia
méme ou plus grande lors de l'héparinisation regionale.
L'hémorragie n'a pas été corrélée avec les anomalies pré-exis-
tantes de Ia coagulation, les traitements anticoagulants,
l'importance de l'azotémie ou Ia possibilité de limiter efficace-
ment l'heparinisation au cours de la dialyse. La fréquence de la
coagulation partielle dans le dialyseur a été de 3 a 5% avec l'un
et l'autre des protocoles. Nous concluons que l'héparinisation
régionale n'a d'advantage ni clinique, ni pratique sur I'utilisation
d'une dose totale faible d'héparine dans Ia prevention du saigne-
ment associé a Ihémodialyse.
have been used that achieve a level of anti-
coagulation adequate to prevent extracorporeal
clotting while limiting the systemic anticoagulation
of the patient. One method is "regional" anti-
coagulation during hemodialysis, which involves in-
fusion of heparin into the blood entering the dialyz-
er, and neutralization by infusion of protamine into
the heparinized blood as it returns to the patient [I-
3]. To avoid bleeding complications from a delayed
heparin effect, additional administration of pro-
tamine several hours after dialysis has been sug-
gested [4]. Theoretically, this method avoids detect-
able systemic anticoagulation of the patient; region-
al heparinization, however, is not used widely
because of the technical difficulties in determining
proper infusion rates of heparin and protamine to
achieve extracorporeal and avoid systemic anti-
coagulation. The other method of limited anti-
coagulation involves low-dose, tightly controlled
heparinization without protamine, as has been pro-
posed recently [5-7]. This method is much simpler,
as it requires monitoring of only extracorporeal
anticoagulation and adjustment of the heparin dose.
Reproducible regional heparinization has been
the procedure of choice in our institution for the
past several years. In spite of good procedural con-
trol, however, severe bleeding continues to be a
cause of serious morbidity in patients at risk, in
view of the lack of detailed comparative studies, we
designed this prospective study to compare the effi-
cacy of regional heparinization with that of limited-
dose, systemic heparinization in preventing both
Anticoagulation with heparin is necessary during
hemodialysis to prevent clotting in the extra-
corporeal circulation. For patients with increased
risk of bleeding, two major modes of heparinization
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dialyzer clotting and bleeding complications in pa-
tients with high risk for hemorrhage.
Methods
Regional heparinization (RH) was performed by
the method of Spencer et al [8] monitoring hepann
therapy with at least 0.5 hourly thrombin clotting
times (TCT) [9, 10]. Heparin (Panheprin, Abbott
Laboratories, N. Chicago, Illinois; or Lipo-Hepin,
Riker Laboratories, Inc., Northridge, California)
was infused into blood before it entered the dialyzer
at a rate calculated to attain a level of 0.3 U of hepa-
rin/mi. Protamine (Protamine Sulfate Injection,
U.S.P., Eli Lilly and Company, Indianapolis, In-
diana) infused into blood leaving the dialyzer was
estimated at approximately I mg of protamine per
100 U heparin and was adjusted to keep the TCT of
the blood returning to the patient near baseline. An
additional dose of 50 mg of protamine was given i.v.
3 hours after dialysis. Low-total-dose hepariniza-
tion (LTH) was performed by intravenous loading
with 5 to 10 U heparin/ib of body wt, and then in-
fusing hepann continuously at a rate of 10 U/lb of
body wt/hr into the blood flowing from the patient
into the dialyzer. Changes in heparin infusion rate
and/or additional small doses of heparin were given
to maintain the extracorporeal TCT at 2 to 3 times
baseline.
Patients were selected for the present study pro-
spectively. All patients in our hemodialysis unit
who required limited heparinization because of
bleeding risk between November 1977 and July
1978 were included. Consecutive patients were as-
signed alternately to two groups: in either group,
serial dialysis treatments during the period of bleed-
ing risk were each performed with RH or LTH on
an alternating schedule; in one group, patients be-
gan the alternating schedule with RH and in the oth-
er group with LTH. With this design, RH and LTH
were distributed with approximately equal frequen-
cy across various degrees of bleeding risk, various
clinical settings, and specific sites of bleeding risk,
and various intervals into the time-course of bleed-
ing risk. All dialyses lasted 3.5 to 5.0 hours and
were performed via arteriovenous shunt or two nee-
dles, one of which might be a femoral vein catheter.
The Cordis Dow hollow-fiber artificial kidney, with
surface area of 1.3 to 2.5 m2, was used in this study
because the noncompliant blood volume of this
dialyzer allowed estimation of the degree of dialyz-
er clotting from the reduction in this volume after
dialysis [11]. The blood flow rates averaged 200 to
210 mI/mm among all dialyses in each hepariniza-
tion protocol.
Bleeding risk was prospectively assessed in all
patients prior to each dialysis. Risk was categorized
as follows: "very high risk" as active bleeding at
the time of dialysis; high risk" as active bleeding
now stopped for less than 3 days, surgical or trau-
matic wounds within the previous 3 days, or acute
dialysis via temporary femoral vein catheter (with a
separate site for blood return); "moderate risk" as
active bleeding now stopped for more than 3 but
less than 7 days, surgical or traumatic wounds of 3
to 7 days duration, or the presence of uremic peri-
carditis; and 'low risk" as more than 7 days
beyond any active bleeding or surgical or traumatic
injury. These risk assessments applied only to a
specific bleeding site, denoted hereafter as the "pri-
mary" site, which was the basis for both a special
heparinization procedure as well as for inclusion in
the study. Bleeding also occurred at unexpected or
unknown sites, and these were denoted as "second-
ary" sites.
Detection of bleeding complications was based
on observation of bleeding or on serial determina-
tions of hematocrit. Observation of gross bleeding
at a primary or secondary site was considered as a
definite complication if it occurred during dialysis,
and as a probable complication if it occurred during
the 24 hours following dialysis. The present study
did not consider minor bleeding complications such
as subconjunctival hemorrhage or minor venipunc-
ture bleeding at the dialysis fistula. Occult bleeding
(for example, gastrointestinal, retroperitoneal) wasjudged to have occurred in the following circum-
stances: (a) a fall in hematocrit of 3 vol% or more
during dialysis confirmed by a repeat determination
at 12 to 24 hours following dialysis; (b) a fall in he-
matocrit of 3 vol% or more in the 24 hours following
dialysis verified by a repeat hematocrit at 24 to 48
hours following dialysis; and (c) any decrease in he-
matocrit despite either blood transfusion or weight
loss of more than 5 lb during dialysis, verified by a
subsequent hematocrit measurement. A second re-
view of the case records was carried out to elimi-
nate any cases with unconfirmed hematocrit
changes, complications that did not represent a
change in the course of previous bleeding, and some
other cause of decline in hematocrit, such as hemo-
lysis.
All patients studied had the following additional
determinations: (a) predialysis and postdialysis
BUN, platelet count, prothrombin time, and partial
thromboplastin time; (b) individual predialysis in
vitro response to heparin at a concentration of 0.3
U/ml whole blood, as described by Spencer et al [8];
(c) residual volume capacity of the dialyzer blood
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compartment after dialysis to estimate the extent of
coagulation in the apparatus [11]; and (d) changes in
vital signs and weight, and recording of all medica-
tion with an effect on coagulation factors, platelet
function, or hematocrit.
Statistical analysis of data included Student's t
test to compare mean values between groups, and
the x2 test to compare frequency of various factors
between groups.
Results
A total of 69 courses of alternating RH and LTH
dialyses, varying in length from one to nine treat-
ments, was studied in 59 patients. Seven patients
entered the study more than one time during the 8-
month period. Four patients with bleeding risk re-
quiring hemodialysis had to be excluded because of
the use of single-needle dialysis or a dialyzer other
Table 1. Distribution of dialyses and complications according to
risk and heparinization protocol
Bleeding
risk N Protocol5
Bleeding complicationsu
Within
24hr
During after
dialysis dialysis Total
Very high 15
16
RH
LTH
3 (20%)
3(19%)
4 (27%)
3 (19%)
7 (47%)
6 (38%)
High 48
47
RH
LTH
5 (10%)
2 (4%)
6 (13%)
3 (6%)
11(23%)
5 (11%)
Moderate 42
53
RH
LTH
2 (5%)
1 (2%)
3(7%)
1 (2%)
5 (12%)
2 (4%)
Low 17
17
RH
LTH
0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
0 (0%)
Total 122
133
RH
LTH
10 (8%)
6 (5%)
13 (11%)
7 (5%)
23 (19%)e
13 (lO%)e
Absolute number (percentage)
RH is regional heparin; LTH, low-total-dose heparin.
P < 0.05, comparing total RH to total LTH for all complica-
tions.
Table 2. Site of bleeding complications'
Bleeding Primary Secondary
risk N Protocol site site
Very high 15
16
RH
LTH
3
4
4
2
High 48
47
RH
LTH
3
1
8
4
Moderate 42
53
RH
LTH
0
0
5
2
Low 17
17
RH
LTH
0
0
0
0
Total 122
133
RH
LTH
6
5
l7
8
Abbreviations are defined in Table
P < 0.05 comparing RH to LTH.
1.
than the hollow-fiber artificial kidney. Equivalent
numbers of dialyses were performed in the setting
of acute and chronic renal failure. Specific clinical
diagnoses necessitating the use of limited heparini-
zation among the 255 dialyses studied included: sur-
gery or trauma in 205 dialyses, gastrointestinal
bleeding in 38 dialyses, genitourinary bleeding in 34
dialyses, pericarditis in 45 dialyses, and femoral
vein or artery catheterization in 48 dialyses. It
should be noted that in 25 of 45 dialyses during pen-
carditis and in 33 of 48 dialyses with femoral vessel
catheterization, there was more than one indication
for limited heparinization.
As shown in Table 1, the 255 dialyses included in
this study were comparably distributed between
RH and LTH protocols and among different degrees
of bleeding risk. Overall, the consecutive and alter-
nating design of this study accomplished the ob-
jective of distributing dialyses similarly between
heparinization protocols, degrees of risk and clini-
cal settings.
Analysis of bleeding complications, also shown in
Table 1, revealed that patients with very high risk
had worsened bleeding during or following dialysis
with both RH and LTH, and that there was no sig-
nificant advantage of one heparinization scheme
over the other in this risk group. The incidence of
bleeding decreased as the risk decreased in both RH
and LTH dialyses, but bleeding tended to be more
frequent with RH than it did with LTH in both the
high and moderate risk dialyses (P <0.10). Overall,
the incidence of hemorrhage was significantly great-
er among all RH than it was among all LTH dial-
yses.
Assigned bleeding risk always referred to a spe-
cific site of potential bleeding. The bleeding compli-
cation, however, frequently did not occur at the pri-
mary site, as shown in Table 2. Occult or unexpect-
ed bleeding episodes at secondary sites tended to be
more frequent with RH dialysis in all risk cate-
gories, and the total number of bleeding complica-
tions at secondary sites was significantly greater
with RH than it was with LTH (P < 0.05).
Factors which could predispose patients to bleed-
ing are shown in Table 3. Coagulation abnormal-
ities, defined as an abnormality in two or more pa-
rameters (TCT, prothrombin time, partial thrombo-
plastin time, and platelet count), commonly related
to the complicated nature of our patients' under-
lying illnesses, but did not correlate with the devel-
opment of bleeding complications. Administration
of concurrent anticoagulant therapy, such as low-
dose heparin and antiplatelet drugs, was not associ-
ated with bleeding complications and was not read-
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ily detectable by routine coagulation testing. The
total heparin dose administered during dialysis did
not differ between patients with and without bleed-
ing complications in either the RH or LTH groups.
The total heparin dose during RH, however, was
four to five times higher than that during LTH, and
the dose of protamine averaged I mg/100 U of hepa-
nfl during RH. Finally, the degree of azotemia be-
fore dialysis was similar in both dialysis groups and
did not correlate with bleeding complications.
Control of systemic heparinization during both
protocols is described in Table 4. The maximum
systemic TCT, a measure of the maximum heparini-
zation of the patient, remained on the average less
than 50% of the TCT for a heparin concentration of
0.3 U/mI during all RH dialyses, and did not differ
significantly between RH dialyses with or without
bleeding complications. Control of LTH procedures
was achieved on the average with a maximum sys-
temic TCT approximating the TCT for a heparin
concentration of 0.3 U/mI, and no statistical dif-
ference between LTH dialyses with or without
bleeding complications. Therefore, RH was associ-
ated with a higher rate of bleeding complications
than was LTH, even though both protocols suc-
ceeded in controlling systemic heparinization as de-
signed.
Dialyzer clotting during RH and LTH protocols
was estimated by the incidence of marked loss in
dialyzer volume during dialysis [11]. The maximum
volume loss during this study was 60%, and suf-
ficient clotting to reduce dialyzer volume by 30% or
more of the original volume occurred in 3% of RH
and 5% of LTH dialyses as shown in Table 5. The
degree of anticoagulation in the dialyzer, deter-
mined by the TCT in extracorporeal blood entering
the dialyzer, ranged from a low value of about twice
the baseline TCT to a high of well above the TCT
for a heparin concentration of 0.3 U/mi in both the
RH and the LTH groups (Tables 4 and 5). Both the
maximum and minimum extracorporeal TCT values
were significantly lower in RH dialyses with clotting
than they were in RH dialyses without marked clot-
ting. These data suggest that dialyzer clotting is un-
common with either protocol. Furthermore, dialy-
zer clotting during RH dialysis is associated with
lesser degrees of extracorporeal heparinization, im-
plying that the large doses of heparin used are nec-
essary to prevent this clotting. Shunt clotting oc-
curred only once during dialysis and was probably
related to local factors rather than to the hepariniza-
tion procedure.
Discussion
The bleeding patient who has renal failure requir-
ing hemodialysis presents the clinical dilemma of
balancing the risk of increased bleeding against the
need to prevent dialyzer clotting with heparin thera-
Table 3. Relation of bleeding complications to possible predisposing factorsa
RH LTH
Bleeding No bleeding Bleeding No bleeding(N = 23) (N = 99) (N = 13) (N = 120)
Preexisting coagulation abnormality1' 7 (30%) 26 (26%) 3 (23%) 28 (23%)
Concurrent anticoagulant drugs" 5 (22%) 12 (13%) 4 (31%) 17 (15%)
Total heparin dose' 176 15 202 8 44 5 47 2
BUNC 95 9 85 4 100 15 86 3
Abbreviations are defined in Table 1. There is no significant difference, for any parameters, between "bleeding" and "no bleeding"
in RH or in LTH.
1) Absolute number (percentages).
Values are means SEM; total heparin dose is in U/lb body wt and BUN is in mg/lOO ml.
Table 4. Control of systemic anticoagulation during dialysis1'
RH LTH
Bleeding
(N 13)
No bleeding(N = 120)Bleeding(N = 23)
No bleeding(N = 99)
Baseline TCT, sec
Maximum systemic TCT,sec
TCTatO.3Uheparinlmlblood,sec
9.3 0.3
13.1 2.1
30.0 4.2
9.3 0.3
11.4 0.6
26.0 1.8
9.7
32.0
25.0
0.3
6.6
3.5
9.6 0.1
27.0 1.7
30.0 1.4
1' There is no significant difference, for any parameters, between "bleeding" and "no bleeding" in RH or in LTH. TCT is thrombin
clotting time; other abbreviations are defined in Table 1. Values are means SEM.
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TableS. Dialyzer clotting during dialysis'
RH LTH
Clotting No clottingClotting No clotting(N 4) (N = 118) (N = 7) (N = 126)
Extracorporeal
TCT, Sec
Maximum 38 6' 72 3b 58 II 59 2
Minimum 17 2C 24 2C 20 3 17 I
There is no significant difference in frequency of clotting be-
tween RH and LTH. Abbreviations are defined in Tables I and 4.
Values are means SEM.p < 0.001, comparing high TCT between clotting and no
clotting.
P < 0.01, comparing low TCT between clotting and no clot-
ting.
py. Advocates for either limited-total-dose heparin-
zation [5—7, 12] or regional heparinization [1—3, 8,
13] have reported their experience, but no detailed
prospective comparison has been presented to date.
Because each method has theoretical advantages,
and because regional heparinization is technically
more difficult to perform, it is of great clinical and
practical importance to determine the comparative
success of these procedures in achieving the opti-
mal balance between bleeding risk and extra-
corporeal anticoagulation.
The data presented here clearly show that well-
controlled regional heparinization is not superior to
closely monitored limited-dose heparinization in the
very high-risk patient with active hemorrhage at the
time of dialysis. Furthermore, regional hepariniza-
tion may be associated with a higher incidence of
hemorrhage from expected and unexpected sites in
all patients with increased risk for bleeding.
Several factors may be responsible for this find-
ing. (a) The dose of heparin required to maintain
adequate regional heparinization is high [1, 2, 8] be-
cause heparin is neutralized on each pass out of
dialyzer back to the patient. Constant infusion of at
least 4000 U of heparinlhr is required to maintain a
heparin concentration of 0.2 to 0.3 U!ml at a dialy-
zer blood flow rate of 200 to 300 mllmin. (b) It is
possible that difficulty in controlling systemic hep-
arinization or unpredictable patient-responsive-
ness to heparin [14, 15] could account for the rate of
bleeding complications in our RH patients. Data
shown in Table 4, however, indicate that neither
systemic over-heparinization nor in vitro evidence
of increased heparin responsiveness was associated
with bleeding complications in this study. (c) The
fate of the heparin-protamine complex in vivo is not
understood well, and the phenomenon of "heparin
rebound" associated with protamine has been im-
plicated in delayed bleeding after dialysis [4, 16]. As
a result, most protocols, like our own, have includ-
ed a late dose of protamine to prevent heparin
rebound. (d) It is also possible that protamine itself
may be responsible for some bleeding complica-
tions [17]; the occurrence, however, of more fre-
quent bleeding complications during as well as after
RH, compared to LTH, suggest that late protamine
is not the only cause of frequent bleeding in the RH
protocol. (e) Two important consequences of hepa-
rin therapy may be platelet loss [18—21] and an ef-
fect of high doses on platelet function [22—24]. In
uremic patients, any decrease in platelet number or
function would further compromise hemostatic
mechanisms and predispose to bleeding.
Regional heparinization might possibly be de-
signed to achieve fewer bleeding complications
through development of protocols using lower
doses. Yet any regional protocol would still necessi-
tate the use of additional equipment, higher doses of
heparin and protarnine, and added coagulation
tests. Therefore, practical considerations, com-
bined with data presented here on bleeding compli-
cations, make limited-dose systemic heparinization
the preferred method in all hemodialysis patients
with risk for bleeding. In extreme circumstances of
life-threatening hemorrhage, peritoneal dialysis re-
mains a possible alternative because heparinization
is not required for this procedure. In many cases
with thoracic or abdominal disease, however, pen-
toneal dialysis is difficult to perform and hemo-
dialysis is necessary.
Our observations for hemorrhage in the 24 hours
after dialysis and at unexpected sites may explain
our high incidence of hemorrhage compared to re-
cent reports concerning patients at risk [5—7]. In
fact, the 10 to 19% incidence in the present study is
comparable to that originally reported by Maher et
a! in their original experience with regional heparin-
ization [2]. Our data suggest that uremic patients
with a known bleeding risk also have a propensity
to hemorrhage from other sites, emphasizing the
need for careful observation for blood loss after as
well as during dialysis, and from occult as well as
expected locations.
In summary, low-total-dose heparinization is at
least as effective as regional heparinization in limit-
ing both clotting in the dialyzer and hemorrhagic
complications in renal failure patients with increased
bleeding risk. The lower cost, technical advantages,
and clinical efficacy make low-total-dose heparini-
zation the preferable mode of anticoagulation in pa-
tients who require hemodialysis while at risk of
bleeding.
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